Technical Analysis for XOMA - XOMA Corporation

Grade Last Price % Change Price Change
B 33.52 2.10% 0.69
XOMA closed up 2.1 percent on Tuesday, July 27, 2021, on 75 percent of normal volume.
Earnings due: Aug 4
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical XOMA trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Outside Day Range Expansion 0.00%
20 DMA Resistance Bearish 2.10%
Outside Day Range Expansion 2.10%
20 DMA Resistance Bearish 0.36%
Narrow Range Bar Range Contraction 3.11%
NR7 Range Contraction 3.11%
20 DMA Resistance Bearish 2.01%
Shooting Star Candlestick Bearish 2.01%
Oversold Stochastic Weakness 2.01%
Older End-of-Day Signals for XOMA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
20 DMA Resistance about 11 hours ago
Rose Above 20 DMA about 11 hours ago
Rose Above Previous Day's High about 11 hours ago
Outside Day about 11 hours ago
Up 3% about 11 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

XOMA Corporation Description

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company offers ACEON, an angiotensin converting enzyme inhibitor. Its proprietary products include gevokizumab, a human engineering (HE) antibody to interleukin-1 beta, which is Phase III studies for non-infectious uveitis and Behçet's uveitis; and Phase II studies for inflammatory acne, erosive osteoarthritis of the hand, active non-infectious anterior scleritis, and cardiovascular diseases. The company's proprietary products also comprise XOMA metabolic activating, sensitizing, and antagonizing/deactivating antibodies that are in preclinical stage for diabetes, metabolic disorders, and other orphan indications; XOMA 3AB, a multi-antibody product, which is in Phase I trial for botulism poisoning; and preclinical programs for autoimmune, cardio-metabolic, infectious, inflammatory, ophthalmological, and oncological diseases. In addition, it develops FDC1, a perindopril arginine and amlodipine besylate, which has completed Phase III trial for hypertension; HCD122 and LFA102 programs that are in Phase I and II, and Phase I trials for hematologic tumors, breast and prostate cancers, and other undisclosed diseases; human monoclonal antibodies, which are in preclinical stage for undisclosed disease targets; and therapeutic antibodies that are in Phase II and Phase I trials for non-small cell lung cancer, solid tumors, and multiple myeloma. Further, the company licenses Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX antibody discovery, optimization, and development technologies. It has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Arana Therapeutics Limited; Kaketsuken; AVEO Pharmaceuticals, Inc.; UCB Celltech; and Genentech, Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Solid Tumors Immune System Infectious Diseases Diabetes Antibodies Monoclonal Antibodies Prostate Cancer Hypertension Non Small Cell Lung Cancer Small Cell Lung Cancer Antibody Cardiovascular Disease Multiple Myeloma Allergy Osteoarthritis Vascular Diseases Cardiovascular Diseases Takeda Pharmaceutical Company Acne Metabolic Disorders Platform Technologies Uveitis Human Monoclonal Antibodies Antibody Product Botulism Inflammatory Angiotensin Angiotensin Converting Enzyme National Institute Of Allergy National Institute Of Allergy And Infectious Diseases Non Infectious Uveitis

Is XOMA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 46.32
52 Week Low 15.48
Average Volume 26,751
200-Day Moving Average 34.38
50-Day Moving Average 31.80
20-Day Moving Average 33.35
10-Day Moving Average 32.56
Average True Range 2.03
ADX 15.14
+DI 17.67
-DI 17.44
Chandelier Exit (Long, 3 ATRs) 32.94
Chandelier Exit (Short, 3 ATRs) 36.08
Upper Bollinger Bands 35.99
Lower Bollinger Band 30.70
Percent B (%b) 0.53
BandWidth 15.85
MACD Line 0.14
MACD Signal Line 0.17
MACD Histogram -0.0347
Fundamentals Value
Market Cap 369.46 Million
Num Shares 11 Million
EPS -0.98
Price-to-Earnings (P/E) Ratio -34.07
Price-to-Sales 147.83
Price-to-Book 9.42
PEG Ratio -0.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 36.74
Resistance 3 (R3) 36.54 35.26 36.20
Resistance 2 (R2) 35.26 34.44 35.36 36.02
Resistance 1 (R1) 34.39 33.94 34.83 34.59 35.84
Pivot Point 33.12 33.12 33.34 33.22 33.12
Support 1 (S1) 32.25 32.30 32.68 32.45 31.20
Support 2 (S2) 30.97 31.79 31.08 31.02
Support 3 (S3) 30.10 30.97 30.84
Support 4 (S4) 30.30